Crossmark

Anti-CD20 Directed Therapy of B Cell Lymphomas: Are New Agents Really Better?

Crossref DOI link: https://doi.org/10.1007/s11912-018-0748-0

Published Online: 2018-11-27

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Freeman, Ciara L.

Sehn, Laurie
License Information

Text and Data Mining valid from 2018-11-27
More Information

Article History

First Online: 27 November 2018

Compliance with Ethical Standards

:

: Ciara L. Freeman has received research funding through grants from Roche and Genentech, has served on advisory boards for AbbVie and Celgene, and has received honoraria for service as a consultant from Seattle Genetics.Laurie Sehn has received research funding through grants from Roche and Genentech and has received honoraria from Roche, Genentech, Seattle Genetics, AbbVie, Celgene, Amgen, Gilead, TG Therapeutics, Pfizer, Karyopharm, Apobiologix, Lundbeck, and Janssen for service as a consultant.

: This article does not contain any studies with human or animal subjects performed by any of the authors.